Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC.
Hofman V, Heeke S, Bontoux C, Chalabreysse L, Barritault M, Bringuier PP, Fenouil T, Benzerdjeb N, Begueret H, Merlio JP, Caumont C, Piton N, Sabourin JC, Evrard S, Syrykh C, Vigier A, Brousset P, Mazieres J, Long-Mira E, Benzaquen J, Boutros J, Allegra M, Tanga V, Lespinet-Fabre V, Salah M, Bonnetaud C, Bordone O, Lassalle S, Marquette CH, Ilié M, Hofman P. Hofman V, et al. Among authors: mazieres j. JTO Clin Res Rep. 2022 Dec 29;4(2):100457. doi: 10.1016/j.jtocrr.2022.100457. eCollection 2023 Feb. JTO Clin Res Rep. 2022. PMID: 36718140 Free PMC article.
Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC.
Ilié M, Mazières J, Chamorey E, Heeke S, Benzaquen J, Thamphya B, Boutros J, Tiotiu A, Fayada J, Cadranel J, Poudenx M, Moro-Sibilot D, Barlesi F, Thariat J, Clément-Duchêne C, Tomasini P, Hofman V, Marquette CH, Hofman P; STALKLUNG01 Study Consortium Investigators. Ilié M, et al. Among authors: mazieres j. J Thorac Oncol. 2021 May;16(5):807-816. doi: 10.1016/j.jtho.2021.01.1617. Epub 2021 Feb 3. J Thorac Oncol. 2021. PMID: 33545389 Free article.
Membranous Nephropathy After Exposure to Immune Checkpoint Inhibitors.
Benyahia R, Lazareth H, Flahault A, Brglez V, Seitz-Polski B, El Fil S, Mazières J, Ribes D, Huart A, Colombat M, Karras A, Belliere J. Benyahia R, et al. Among authors: mazieres j. Kidney Int Rep. 2023 Jun 8;8(9):1892-1898. doi: 10.1016/j.ekir.2023.06.001. eCollection 2023 Sep. Kidney Int Rep. 2023. PMID: 37705909 Free PMC article. No abstract available.
'Double-bifurcated' stent: when 3D is not an option.
Guibert N, Mazières J, Moreno B, Dutau H, Plat G, Héluain V, Kessler R, Porzio M. Guibert N, et al. Among authors: mazieres j. Thorax. 2023 Jul;78(7):735-736. doi: 10.1136/thorax-2022-219954. Epub 2023 Mar 29. Thorax. 2023. PMID: 36990692 No abstract available.
Druggable redox pathways against Mycobacterium abscessus in cystic fibrosis patient-derived airway organoids.
Leon-Icaza SA, Bagayoko S, Vergé R, Iakobachvili N, Ferrand C, Aydogan T, Bernard C, Sanchez Dafun A, Murris-Espin M, Mazières J, Bordignon PJ, Mazères S, Bernes-Lasserre P, Ramé V, Lagarde JM, Marcoux J, Bousquet MP, Chalut C, Guilhot C, Clevers H, Peters PJ, Molle V, Lugo-Villarino G, Cam K, Berry L, Meunier E, Cougoule C. Leon-Icaza SA, et al. Among authors: mazieres j. PLoS Pathog. 2023 Aug 24;19(8):e1011559. doi: 10.1371/journal.ppat.1011559. eCollection 2023 Aug. PLoS Pathog. 2023. PMID: 37619220 Free PMC article.
Transcriptomics profiling of the non-small cell lung cancer microenvironment across disease stages reveals dual immune cell-type behaviors.
Hurtado M, Khajavi L, Essabbar A, Kammer M, Xie T, Coullomb A, Pradines A, Casanova A, Kruczynski A, Gouin S, Clermont E, Boutillet L, Senosain MF, Zou Y, Zhao S, Burq P, Mahfoudi A, Besse J, Launay P, Passioukov A, Chetaille E, Favre G, Maldonado F, Cruzalegui F, Delfour O, Mazières J, Pancaldi V. Hurtado M, et al. Among authors: mazieres j. Front Immunol. 2024 Oct 31;15:1394965. doi: 10.3389/fimmu.2024.1394965. eCollection 2024. Front Immunol. 2024. PMID: 39606240 Free PMC article.
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer.
Solomon BJ, Liu G, Felip E, K Mok TS, Soo RA, Mazieres J, Shaw AT, Marinis F, Goto Y, Wu YL, Kim DW, Martini JF, Messina R, Paolini J, Polli A, Thomaidou D, Toffalorio F, Bauer TM. Solomon BJ, et al. Among authors: mazieres j. Future Oncol. 2024 Oct 3:1-11. doi: 10.1080/14796694.2024.2406117. Online ahead of print. Future Oncol. 2024. PMID: 39360949
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.
Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S; KEYNOTE-671 Investigators. Spicer JD, et al. Lancet. 2024 Sep 28;404(10459):1240-1252. doi: 10.1016/S0140-6736(24)01756-2. Epub 2024 Sep 14. Lancet. 2024. PMID: 39288781 Clinical Trial.
Sarcoid-like reaction related to ALK-ROS inhibitors in lung cancer patients.
Morin C, Villeneuve T, Norkowski E, Rosencher L, Cadranel J, Mazières J. Morin C, et al. Among authors: mazieres j. Respir Med Res. 2024 Aug 30;86:101138. doi: 10.1016/j.resmer.2024.101138. Online ahead of print. Respir Med Res. 2024. PMID: 39288551 No abstract available.
325 results